Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity?
Paolo Severino, Andrea D’Amato, Silvia Prosperi, Alessandra Dei, Anna Vittoria Mattioli, Antonio Cevese, Giuseppina Novo, María Prat, Roberto Pedrinelli, Riccardo Raddino, Sabina Gallina, Federico Schena, Corrado Poggesi, Pasquale Pagliaro, Massimo Mancone, Francesco Fedele
Abstract
Heart failure (HF) is a clinical syndrome defined by specific symptoms and signs due to structural and/or functional heart abnormalities, which lead to inadequate cardiac output and/or increased intraventricular filling pressure. Importantly, HF becomes progressively a multisystemic disease. However, in August 2021, the European Society of Cardiology published the new Guidelines for the diagnosis and treatment of acute and chronic HF, according to which the left ventricular ejection fraction (LVEF) continues to represent the pivotal parameter for HF patients' evaluation, risk stratification and therapeutic management despite its limitations are well known. Indeed, HF has a complex pathophysiology because it first involves the heart, progressively becoming a multisystemic disease, leading to multiorgan failure and death. In these terms, HF is comparable to cancer. As for cancer, surviving, morbidity and hospitalisation are related not only to the primary neoplastic mass but mainly to the metastatic involvement. In HF, multiorgan involvement has a great impact on prognosis, and multiorgan protective therapies are equally important as conventional cardioprotective therapies. In the light of these considerations, a revision of the HF concept is needed, starting from its definition up to its therapy, to overcome the old and simplistic HF perspective.